Ikarian Capital, LLC Bio Atla, Inc. Transaction History

Ikarian Capital, LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$19.0 - $30.95 $3.73 Million - $6.08 Million	-196,400 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$29.44 - $43.74 $3.72 Million - $5.52 Million	126,240 Added 179.93%	196,400 $5.78 Million
Q1 2021 May 17, 2021	BUY	$32.41 - $70.91 $2.27 Million - $4.98 Million	70,160 New	70,160 $3.57 Million

17.3M

500

33.5K

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $62.4M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.